These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9106022)

  • 1. Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Adamo V; Maisano R; Pergolizzi S; Altavilla G; Caristi N; Chiofalo G; Scimone A; Settineri N
    J Chemother; 1997 Feb; 9(1):72-6. PubMed ID: 9106022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
    Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Gebbia V; Valenza R; Testa A; Borsellino N; Cannata G; Restivo S; Speciale R; Ingria F; Spadafora G; Gebbia N
    ORL J Otorhinolaryngol Relat Spec; 1994; 56(5):279-82. PubMed ID: 7526312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
    Grégoire V; Beauduin M; Humblet Y; Hamoir M; Longueville J; Majois F; Remacle FM; Rousseau F; Salamon E; Wambersie A
    J Clin Oncol; 1991 Aug; 9(8):1385-92. PubMed ID: 2072142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK
    Cancer; 2001 Apr; 91(7):1316-23. PubMed ID: 11283932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
    Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
    Galetta D; Giotta F; Rosati G; Gebbia V; Manzione L; Di Bisceglie M; Borsellino N; Colucci G
    Anticancer Res; 2005; 25(6C):4445-9. PubMed ID: 16334124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
    Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
    Recondo G; Armand JP; Tellez-Bernal E; Domenge C; Belehradek M; De Vathaire F; Wibault P; Richard JM; Cvitkovic E
    Laryngoscope; 1991 May; 101(5):494-501. PubMed ID: 1709437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.
    Wang TF; Chu SC; Kao RH; Yao CY; Li CC
    Jpn J Clin Oncol; 2008 Jul; 38(7):459-63. PubMed ID: 18586668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study.
    Fountzilas G; Athanassiadis A; Samantas E; Skarlos D; Kalogera-Fountzila A; Nikolaou A; Bacoyiannis H; Stathopoulos G; Kosmidis P; Daniilidis J
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-65-S2-67. PubMed ID: 9045340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer.
    Huber MH; Lippman SM; Benner SE; Shirinian M; Dimery IW; Earley CL; Winn RJ; Brooks J; Baez L; Hong WK
    Ann Oncol; 1995 Jan; 6(1):83-5. PubMed ID: 7536031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
    J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer.
    Kucukzeybek Y; Gorumlu G; Karaca B; Erten C; Cengiz E; Kemal Gul M; Karabulut B; Uslu R; Sanli UA; Goker E
    J BUON; 2008; 13(2):199-203. PubMed ID: 18555465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Thödtmann F; Theiss F; Kemmerich M; Heinrich B; Laubenbacher C; Quasthoff S; Kau R; Herzog M; Diergarten K; Hanauske AR
    Ann Oncol; 1998 Mar; 9(3):335-7. PubMed ID: 9602270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
    Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer.
    Ferrari D; Fiore J; Codecà C; Di Maria G; Bozzoni S; Bordin V; Caldiera S; Luciani A; Zonato S; Floriani I; Foa P
    Anticancer Drugs; 2009 Mar; 20(3):185-90. PubMed ID: 19396017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.